在ALS中反意义疗法的意义
Sien H Van Daele1, Pegah Masrori2, Philip Van Damme2
1KU Leuven - University of Leuven, Department of Neurosciences, Leuven Brain Institute (LBI), Leuven, Belgium; Laboratory of Neurobiology, VIB Center for Brain & Disease Research, Leuven, Belgium; Department of Human Genetics, University Hospitals Leuven, Leuven, Belgium.
Trends in molecular medicine
|January 12, 2024
概括
反感性寡核酸 (ASOs) 代表了治疗肌缩侧面硬化症 (ALS) 的新时代. 这种方法显示出停止和潜在地逆转ALS进展的希望,为患者提供希望.
科学领域:
- 神经学 神经学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 肌缩侧面硬化症 (ALS) 治疗正在推进新的治疗策略.
- 反感性寡核酸 (ASOs) 已经显示出有前途的结果,并获得了美国食品和药物管理局 (FDA) 对ALS治疗的批准.
- 目前的ASO成功主要在于家族性ALS,但对零星ALS的应用正在出现.
研究的目的:
- 审查目前的反感性寡核酸 (ASO) 疗法在肌缩侧面硬化症 (ALS) 的现状.
- 讨论使用ASO用于ALS治疗的潜在好处和挑战.
- 探索新兴的ASO应用,用于家族性和零星性ALS.
主要方法:
- 关于ALS的ASO疗法的当前文献的综述.
- 对FDA批准的ASO治疗方法的分析.
- 检查正在进行的临床试验对ALS的ASO干预措施的审查.
- 讨论针对基因修饰剂和错误拼接事件的ASO策略.
主要成果:
- ASO疗法标志着ALS治疗的重大进展.
- 令人鼓舞的结果表明,ASO可以阻止并可能逆转ALS的进展.
- ASO的有效性主要在罕见的家族形式的ALS中被证明.
- 早期试验正在探索ASO在零星ALS和基因修饰剂干扰中的使用.
结论:
- ASO疗法为治疗肌缩性侧面硬化症提供了一个有希望的新前沿.
- 进一步的研究和临床试验对于更广泛的ALS患者群体优化ASO策略至关重要.
- 了解ASO的可能性和陷对于未来的ALS治疗开发至关重要.
相关概念视频
02:30siRNA - Small Interfering RNAs
16.8K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:15Parkinson's Disease: Overview
551
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
551
01:24Parkinson's Disease: Treatment
272
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
272
01:23RNA Interference
26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K
02:15Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K